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Abstract
Objectives
To explore patients’ concepts of stiffness in polymyalgia rheumatica (PMR), and how they
think stiffness should be measured.
Methods
Eight focus groups were held at three centres involving 50 patients with current/previous
PMR. Each group had at least one facilitator and one rapporteur making field notes. An in-
terview schedule was used to stimulate discussion. Interviews were recorded, transcribed
and analysed using an inductive thematic approach.
Results
Major themes identified were: symptoms: pain, stiffness and fatigue; functional impact; im-
pact on daily schedule; and approaches to measurement. The common subtheme for the
experience of stiffness was “difficulty in moving”, and usually considered as distinct from the
experience of pain, albeit with a variable overlap. Some participants felt stiffness was the
“overwhelming” symptom, in that it prevented them carrying out “fundamental activities” and
“generally living life”. Diurnal variation in stiffness was generally described in relation to the
daily schedule but was not the same as stiffness severity. Some participants suggested
measuring stiffness using a numeric rating scale or a Likert scale, while others felt that it
was more relevant and straightforward to measure difficulty in performing everyday activi-
ties rather than about stiffness itself.
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Conclusions
A conceptual model of stiffness in PMR is presented where stiffness is an important part of
the patient experience and impacts on their ability to live their lives. Stiffness is closely relat-
ed to function and often regarded as interchangeable with pain. From the patients’ perspec-
tive, visual analogue scales measuring pain and stiffness were not the most useful method
for reporting stiffness; participants preferred numerical rating scales, or assessments of
function to reflect how stiffness impacts on their daily lives. Assessing function may be a
pragmatic solution to difficulties in quantifying stiffness.
Introduction
Polymyalgia rheumatica (PMR) is an inflammatory musculoskeletal disease that affects older
people. Core clinical features for the diagnosis of PMR include bilateral shoulder and/or hip
pain, morning stiffness, and abnormal inflammatory markers such as the erythrocyte sedimen-
tation rate [1]. “Morning stiffness” is considered an important diagnostic clue to presence of
inflammatory symptoms, to differentiate “inflammatory” disorders such as PMR and rheuma-
toid arthritis (RA) from “non-inflammatory” disorders such as osteoarthritis [2]. PMR is treat-
ed with glucocorticoids (steroids), often for several years [2,3], at the cost of a significant
burden of risks and adverse effects in this age group.[1] Monitoring disease activity in treated
patients is therefore important, and may require physicians to ask different questions than they
would use for diagnosis. Patient-reported outcome measures that capture the impact of the dis-
ease on patients’ lives are required for a core outcome set [4] that will allow optimal treatment
strategies to be developed.
Current clinical guidelines recommend that patients treated for PMR should be monitored
on the basis of symptoms (proximal pain, fatigue and morning stiffness), since conventional in-
flammatory markers can be misleading in PMR [1]. Factor analysis of an observational dataset
suggested that morning stiffness duration, pain and laboratory markers may reflect different
dimensions of disease [5]. However, it is not clear whether measures of stiffness and pain in
PMR appear to diverge because they represent two distinct experiences of PMR, or because
stiffness and pain are part of the same patient experience but stiffness is more difficult to mea-
sure accurately; morning stiffness duration has been reported to have poor test-retest reliability
in PMR [6].
In preliminary informal discussions with groups of patients with PMR [5,7], patients rarely
mentioned “morning stiffness”; and to some patients, stiffness and pain seemed to be part of
the same experience. This challenged our preconceptions that the patient experience of stiff-
ness in PMR could map directly onto the physician’s concept of inflammatory symptoms or
“morning stiffness”. Qualitative research can produce novel insights into the patient experience
in inflammatory disease [8]; here, we chose a qualitative approach to explore the patients’ con-
cepts of stiffness and identify potentially valid ways of assessing or measuring stiffness in pa-
tients with glucocorticoid-treated PMR.
Focus group methodology allows discussion between participants [9] and the identification
of common and individual experiences while minimising the influence of the researchers on
their discussion [9, 10].
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Patients and Methods
Ethical approval was received from NRES Committee London-City and East (Ref: 12/LO0120:
Mr Raj Khullar at the South West REC Centre, Whitefriars, Level 3, Block B Lewins Mead,
Bristol, BS1 2NT); and governance approval was received from hospital research and develop-
ment committees at Ashford and St Peter’s Hospital NHS Trust, Leeds Teaching Hospitals
NHS Trust, and University Hospitals Bristol NHS Trust. Patients with a rheumatologist-con-
firmed diagnosis of PMR who were receiving treatment either currently or within the previous
three years were invited to participate in focus groups. Prior to data collection all participants
were provided with an information sheet and written informed consent was provided in ad-
vance, in line with the Declaration of Helsinki.
At all stages of the project, from planning the protocol to analysis and writing the results,
advice and input was received from co-authors MN and JD, patient research partners with per-
sonal experience of PMR in accordance with the European League Against Rheumatism
(EULAR) recommendations for patient research involvement [11].
Participants (n = 50; 36 females) were purposively selected from secondary care (rheumatol-
ogy) clinics at three geographically distinct UK NHS trusts aiming for diversity of age, gender
and disease duration. (Table 1).
Each focus group had one facilitator managing the contributions of each group member,
and one rapporteur who made field notes to aid transcription accuracy. A common interview
schedule was used (Table 2). The schedule was structured to elicit patient’s understanding and
experience of PMR stiffness, how it impacted upon them, associated symptoms, diurnal varia-
tion and effectiveness of corticosteroid treatment, before asking them how they might measure
stiffness to reflect their individual experiences. However, broader discussion emerged as pa-
tients began asking questions pertinent to them. These were monitored to ensure the purpose
of the interview was maintained.
Focus group discussions were digitally recorded, transcribed verbatim, anonymised, and
cross-checked by group facilitators. The two Bristol focus groups took place after initial
Table 1. Participants in focus groups at the three centres.
Chertsey (n = 19) Leeds (n = 19) Bristol (n = 12)
Number of focus groups conducted 3 3 2
Females, n (%) 13 (68%) 14 (74%) 9 (75%)
Age, years, median (range) 66 (59–79) 76 (53–84) 77 (45–86)
Disease duration, months, median (range) 28 (6–72) 9 (1–51) 15.5 (2–30)
White, n (%) 19 (100%) 19 (100%) 12 (100%)
doi:10.1371/journal.pone.0126758.t001
Table 2. Pre-defined interview schedule, used for all eight focus groups.
Question
number
Question content
1 Deﬁnition of stiffness in words
2 Grading of severity of stiffness
3 Why is stiffness important, and how is it different from pain?
4 Does stiffness vary through the day and night, and should this be accounted for in
measurement?
5 How does treatment change stiffness reporting?
6 (Bristol only) If your PMR was an animal, what would it be?
doi:10.1371/journal.pone.0126758.t002
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examination of data from the Chertsey and Leeds focus groups, allowing an extra question to
be added to further promote discussions: ‘If your PMR was an animal what would it be?’ This
question has been used in previous research to help patients describe their inflammatory ar-
thritis and how this impacted upon them [12; 13].
Six stages of inductive thematic analysis were performed [14]: familiarization with the data;
generation of initial codes by direct annotation of transcripts; searching for themes; reviewing
themes; defining themes; and naming themes. In addition the penultimate interpretation was
discussed with the two patient partners to check their interpretation of the data before the
themes and their interpretation were finalised [11, 14]. Utilising focus groups and a broad in-
terview schedule, we adopted a social constructionist perspective [15].
Analysis was led by MM, an experienced qualitative researcher who had not been involved
in data collection, with input from all co-authors. Firstly the transcripts were systematically re-
read and compared (MM read all transcripts; SLM read the Leeds transcripts; MW read the
Chertsey transcripts) and initial data interpretation was discussed. Secondly two researchers
(MM, SLM) returned iteratively to the annotated transcripts from all three sites, checking the
validity of the interpretation of the data by clarifying meanings and codes, and building these
up into themes guided by several rounds of discussion. As themes and sub-themes became de-
fined, a conceptual model was developed to illustrate the interrelationships of these themes. As
the intention of this work was to inform the development of a core outcome set for PMR, the
development of this model was informed by the World Health Organisation International
Classification of Functioning, Disability and Health, which classifies outcome measures into
those affecting body functions and structure, activity and participation.[16]
In this report, direct quotes are annotated with the centre (SPH: St Peter’s Hospital, Chert-
sey; L, Leeds; B, Bristol) followed by the focus group number, the gender of the speaker and the
line number(s) of the relevant transcript.
Results
To present these data, themes will be cited in italics and verbatim quotes identified by location/
focus group/gender/line number. Guided by the interview schedule, stiffness was discussed in
relationship to pain, but participants also identified fatigue as an important symptom in PMR.
Stiffness tended to be discussed in terms of impact on their functional ability (PMR affects the
things we do); and on how they structured their day because of the 24-hour (diurnal) variation
in symptom severity (impact on daily schedule: PMR always on your mind).Measurement of
stiffness was influenced by all of these themes and provided a complementary perspective on
patients’ experience of stiffness in PMR. Themes were also identified relating to the emotional
and social impact of the symptoms, and participants’ use of self-management strategies to min-
imise the disruption to their lives. While clearly important to these patients, this was felt to go
beyond the original research question relating to measurement of stiffness itself, therefore
these will be presented in a separate report.
These themes interrelate (Fig 1) and are illustrated by exemplar verbatim quotes in Table 3.
Stiffness: won’t move
The labels “stiffness” and “pain”, often used interchangeably, were felt to be ways of conveying
the unfamiliar experience of PMR.
“I think (the thing) is that the—the—we call it pain or call it stiffness . . . but there are certain
things that are indicators that something’s not right. [SPH/3/F/945-51]
Stiffness in Polymyalgia Rheumatica
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“I never had anything like it, nothing like. I’ve never had anything like it ever.” [B/1/M/265-
6]
Stiffness was defined as a restriction of movement, and was a different experience from
pain, even if sometimes both were experienced together. Participants kept returning to the idea
that it was easiest to describe stiffness in terms of what it stopped them doing, which included
many everyday or “fundamental” activities.
“Er I had a very sore shoulder, and that was pain there. But then one morning I woke up and
I can only say I felt I was in a coffin, in that restricted place, absolutely solidly stiff.”[L/2/F/
609-11]
“Yeah well about hard to define it, it’s hard to get up out of a chair, I know that.” [B/1/M/
1849-50]
Asked to elaborate further, participants explained stiffness using mechanical ideas: for ex-
ample, a machine that was not working (loss of control), or their body moving through a vis-
cous substance or being weighed down by something very heavy (which could in itself be
painful). These quotes illustrate the close relationship of the idea of stiffness to the idea
of movement.
“I completely like lost my drives, if you like, in a machine, like my drives, complete lack of
power.” [B/1/M/724-5]
“Well I used to think my brain’s [laughs] not telling me how to get out the bath. I—I couldn’t
push on my arms or anything like that.” [SPH/3/F/90-91]
Fig 1. Final conceptual model of the patient experience of stiffness in PMR and aspects that may be relevant to measurement of stiffness. This
model reflects the major themes, derived from the data generated by participants with PMR, highlighting the importance of key symptoms and their impact on
daily life: limiting function and a constant reminder. Pain and stiffness for many are inextricably linked, with one or other dominating their PMR experience or
on occasion difficult to separate out. Outcomemeasures might address the intensity of symptoms and/or restriction of activities.
doi:10.1371/journal.pone.0126758.g001
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“And I’ve tried to analyse whether I’m so stiff because it hurts to go down[stairs] faster, or
whether it’s like a gloopy glue that you’re trying to work your way through, which I find quite
strange.” [SPH/2/F/95-98]
“Stiffness is the worst. I’ve got it at the moment. And I try to turn round to you, it is like I have
um bricks on top of each other, cemented onto my neck. It is really heavy and it is very uncom-
fortable.” [SPH/2/F/268-71]
Ache/pain: hurts regardless of movement
Some participants preferred the word ache rather than pain.
“It wasn’t a pain um I get sometimes in my arms at night now, but it’s like a toothache, it’s
more like an ache, you know.” [SPH/3/F/41-3]
However particularly prior to initiation of glucocorticoid treatment, some participants re-
ported that their pain was overwhelming and real, dominating all other symptoms.
Table 3. Themes identified during the analysis.
Overarching theme Theme Subtheme Quotations
Body symptoms Stiffness “Won’t move” “Um I don’t know that you’re conscious of being stiff without
moving something.” [SPH/3/M/821-6].
Unfamiliar experience “I’ve never had anything like it ever.” [B/1/M/265-6]
Making sense of stiffness Loss of control “It’s as if you’ve lost control of—of—of your movement. It’s—it’s—
you’re wanting to do it like mad, but something else is [laughs]
stopping you.” [L/1/F/835-41]
Resistance to
glucocorticoids
I would agree that you have the pain till the steroids kick in and get
rid of it. And then the stiffness comes afterwards really. [B/2/F/438]
Ache/pain: “hurts”
(regardless of movement)
Overwhelming pain “The pain that I got from PMR was mind-blowing and virtually
unique.” [SPH/2/M/1220-1]
Ache (a pain that could
be ignored)
“When it was sort of bearable it was just like a dull ache” [B/1/M/
381-2]
Overlap of stiffness and
pain (“hurts to move”)
Stiffness with pain “they’re intrinsically linked, pain and stiffness. . . So you lift your
arm, and it’s stiff, and then the pain is excruciating, that’s how I’d
explain it.” [SPH/3/F/176-87]
Stiffness is pain “stiffness is painful, the feeling is painful” [L/3/F/305-6]
Fatigue (tiredness) and
sleep disturbance
Fatigue always
present
“Stiffness is in the background. I get up and I straighten up and
then it’s forgotten. But the um tiredness, the fatigue, is always
present.” [B/2/M/742-4]
Impact on function: PMR
affects what we can do.
“Fundamental” (everyday
or valued) activities
“It’s um hmm, a bad day for me would be when I have difﬁculty
moving about, getting up from a chair, moving about, cooking”. [L/
1/M/628-31]
Impact on daily schedule:
PMR always on your mind
24-hour cycle of symptom
severity
Anticipation “But I knew what I was going to have in the night. I’d go off to
sleep ﬁne. But I would wake up 3.00 and 4.00, from then on till
midday the next day I would be in agony.” [SPH/3/F/378-89]
Measuring stiffness in PMR Measure stiffness directly A 1 to 10 scale I would measure it from 1–10.” [SPH/1/F/270-9]”I wouldn’t like to
grade anything on a 1–10 basis personally” [L/1/F]
Duration of morning
stiffness
“Um I ﬁnd that very difﬁcult to quantify. Um because it’s not the
same every day.” [L/1/M]
Measure indirect effects of
stiffness
Ability to perform
everyday activities
“you could say how difﬁcult or not difﬁcult it was getting up and
down the stairs or getting up and out of bed.” [SPH/1/F/1963-7]
doi:10.1371/journal.pone.0126758.t003
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“Pain, it’s like when they say about childbirth, you’ve forgotten it straight away, you know,
pain you do forget. Except I can remember the real extreme.” [SPH/1/F/932-4]
“But when I started with the real pain, it was 4thNovember, you know, just at 4 o’clock on the
Friday night.” [L/2/F/127-129]
Pain was often not well-localised to the joints, but they described vivid images of how the
pain was felt:
“I felt that all my muscles had been torn” [SPH/1/F/477]
“As if somebody had punched me all over” [SPH/1/F/151-2] “like you’ve been steamrollered
by a bus . . . been through a mangle” [SPH/1/F/3149]
Pain tended to be responsive to medication, whereas responsiveness of stiffness to glucocor-
ticoids varied between individuals:
“I feel as if the stiffness is the overwhelming symptom. I can put up with the pain. But it takes
over, it seems to come from nowhere and take over your body. You’ve got—you’ve no sort of—
there’s nothing you can actually do, is there?Whereas you can take a couple of paracetamols
and shift the pain. But the stiffness was my problem.” [L/1/F/396-401]
“Female 1: I would agree that you have the pain till the steroids kick in and get rid of it. And
then the stiffness comes afterwards really. Because, well, you may have had it all along, but
you don’t realise it because there’s pain.
Female 2: I haven’t got any stiffness now. Do you have stiffness after you’ve had steroids?
Female 1: Oh yeah I still get stiff.” [B/2/F’s/438-46]
Participants spent some time discussing whether other conditions could complicate assess-
ment of pain and stiffness; although they were clear that the symptoms prior to treatment were
definitely PMR, some participants expressed uncertainty as to whether persistent pain and
stiffness symptoms in treated PMR were due to the PMR itself or another cause, such as
osteoarthritis.
Overlap of stiffness and pain
Several patients described pain and stiffness as two separate experiences:
“Well it’s two different things to me. The pain is one thing and the stiffness is another. Now if
I’m not stiff, I’m OK.” [L/1/F/769-70]
For others, pain and stiffness occurred at the same time, especially when movement pro-
duced an increase in pain:
“stiffness is painful” [L/3/F/305-6]
Stiffness in Polymyalgia Rheumatica
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For others, the words pain and stiffness were used almost interchangeably, suggesting the
two symptoms were inextricably linked, or two facets of the same experience, which can make
measuring stiffness complicated:
“I probably just started off with a general sort of ache, a stiffness. Um because I always used to
go to quite a lot of classes, sort of aerobics and things, and when I came back I wasn’t sort of
recovering quite as well. You know, I always ached a bit when I came back, but I was aching a
lot more, really stiff. Um and I just thought, “Oh it’s me age, I’ll just sort of work through it.”
But then sort of like three months on, like you, it was sort of in bed and just—just agony, just
really stiff, I couldn’t sort of get me jumpers on or anything without help.” [L/1/F/88-97]
Fatigue and sleep disturbance
Both stiffness and pain contributed to sleep disturbance, with turning over in bed often de-
scribed as nearly impossible without waking. Sleep disturbance was a prominent feature of
PMR for many participants:
“I think sleep is a major problem, yeah I really do.” [SPH/1/M/1575].
“I might be asleep and just move in my sleep, and—and that woke me straight up.” [L/3/F/
763-4]
Fatigue, often called “tiredness”, seemed to be pervasive (always present) and was seen as
more than simply an effect of insufficient sleep; it was described as a significant symptom of
PMR with its own diurnal rhythm:
“Stiffness is in the background. I get up and I straighten up and then it’s forgotten. But the um
tiredness, the fatigue, is always present.” [B/2/M/742-4]
“Now I felt very tired um during the back end of last summer. Er I felt, from about, oh, 3
o’clock in the afternoon I’d feel really, really tired.” [L/2/F/125-127]
Although there was variation in the severity and diurnal pattern of fatigue, pain and stiffness
between individual patients, all reported an impact on physical function.
PMR affects what we can do
With stiffness present, everyday activities became “like walking through treacle” [L/2/F/1236-
8]. Some participants saw the most important aspect of PMR as whether or not they could per-
form common activities of daily living, such as getting up in the morning, dressing and moving
around the house, and other valued activities (such as golf, walking the dog, playing badmin-
ton, or caring for family members).
For many participants, pain did not stop them doing their valued activities but stiffness did.
“And it—it was really the impediment of movement that I was er suffering, rather than pain
in itself. In other words, I do get quite a lot of—of pain er with it. But the pain doesn’t actually
stop me doing things. The stiffness does, it’s a much greater impediment, I think, to um er—to
generally living life.” [L/1/M/177-181]
Stiffness in Polymyalgia Rheumatica
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“Sorry—on the days that I can’t get up the stairs say easily, I’m not sure whether I’m stiff or
I’m in pain, to be honest. Because I go up on all fours, that’s the only way I can get up there.”
[SPH/1/F/579-82].
Impact on daily schedule: PMR always on your mind
PMR symptoms had a 24-hour cycle of severity; usually all symptoms were worst in “the small
hours” of the morning or on waking, although for some participants, pain predominated at
night and stiffness during the day.
“I think nights were pain, really painful . . . And through the day was more stiffness.” [B/1/F/
1586-90]
“You dread the morning to come. You don’t want to wake up” [B/1/F/143]
The diurnal variation in symptoms was dramatic, and prompted several participants to
reorganise their activities to the afternoon.
“Now I can guarantee that in a morning I can hardly get up, but by 2 o’clock it’s gone.” [L/3/
F/44-45]
Measuring stiffness
When asked what and how they would measure stiffness and pain, some participants suggested
a numerical rating scale (such as “1 to 5” or “1 to 10”) and some preferred words (“mild,moder-
ate or severe”); no patient suggested visual analogue scales, a common patient outcome mea-
sure. However, rating scales were generally felt to need more context than simply a grading of
the symptoms, for example assessment of the ability to perform everyday activities.
“It depends on how you would apply the scale” [L/1/M/1020]
“If you can’t get out of bed to go to the toilet there’s something seriously wrong with you, isn’t
there? And from that point of view I was 10” [L/3/F/446-8]
“And I think descriptive really, rather than 0–10. Say—say you’re doing it um through the
day, and the first one you do is in the morning, you could say how difficult or not difficult it
was getting up and down the stairs or getting up and out of bed.” [SPH/1/F/1963-7].
“It’s more related to activity, I think, as far as I was—I’m concerned.” [L/1/F/ 563–4]
One participant wondered if stiffness could be quantified using a mechanical device:
“Could you measure functionality of a limb against a—like a spring or something.” [SPH/2/
M/533-4])
After prompting from the facilitator, some agreed that duration of morning stiffness was an
aspect that could be measured, since this related to the diurnal variation in symptom severity.
Stiffness in Polymyalgia Rheumatica
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However this was reflected back more in terms of function rather than using the word
stiffness itself.
“You know, you know, er it’s just—there’s no um—but I think the sort of morning one would
be quite a good one for me, how long it takes you to get—get going really.” [L/1/F/1230-3]
However, duration of morning stiffness was rarely volunteered spontaneously as a sugges-
tion for how stiffness might be measured, possibly due to stiffness being difficult to quantify
due to daily variation.
“Um I find that very difficult to quantify. Um because it’s not the same every day.” [L/1/M/
1230-1]
Another participant suggested measuring the change in severity of stiffness over the day,
rather than duration of stiffness itself:
“I would measure it, in my mind, I would measure it from 1–10, how you feel when you get
up in the morning, and grade it in numbers, as 10 being the worst, and grade it down to 1,
throughout the day, so you know where you are on a level. Because during the day you do feel
differently.” [SPH/1/F/274-9]
Participants reported that the symptoms in treated PMR were the same as in untreated
PMR “but very much reduced”, suggesting that it would be valid to measure them in the same
way before and after treatment. “What about measuring it every time you go down a notch on
your steroids? So then you measure for a week.” [SPH/1/F/1892-3]
Four major points emerge from these results. First, patients’ experience of stiffness in PMR
can be characterised under eight themes. These fall under overarching headings of bodily
symptoms, impact on function, impact on daily schedule and measuring stiffness. Second,
many patients found it difficult to distinguish between pain and stiffness, and often used the
words interchangeably. Others were able to distinguish them and reported that they had differ-
ent consequences. Third, the measurement of the impact of stiffness might be best undertaken
by the assessment of function. Fourth, the consequences of the symptoms of PMR permeated
everything to do with patients’ daily routine. A further observation is that it may prove difficult
to discover the attribution of symptoms which may persist or recur after successful treatment
with glucocorticoids.
Discussion
This aim of this study was to explore the patient’s concept of “stiffness” in PMR to ensure that
it is measured in a way that is relevant to this. The relationship between stiffness and pain ap-
peared more complex than we had anticipated; furthermore many patients reported fatigue as
a significant problem in PMR. Stiffness was defined as inability to move; this loss of control of
the body had a devastating impact on ability to perform everyday activities, and participants
felt that assessing changes in functional ability would be a valid, though indirect, way to assess
changes in stiffness itself.
Participants told us that pain/ache responded well to medication, particularly glucocorti-
coids, but stiffness responded more variably, and fatigue even less well. Indeed, in most previ-
ous studies, not all patients with PMR have a complete response to glucocorticoids [2, 6, 17–
18]. This illustrates the contrast between the distillation of diagnostic features in the history
from the physician’s perspective [1, 19] and the complexity of the patient experience,
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particularly once established on glucocorticoids. Whether the persistent symptoms reported by
many patients were part of the PMR itself or were due to other conditions is a question that
could not be answered within this research study, as it would require a full clinical assessment.
Assessment of stiffness does not appear to be straightforward. Rating scales for stiffness it-
self were suggested by some, but were felt to lack context. Some patients found the difference
between pain and stiffness difficult to characterise, but nevertheless it appears important to
measure the symptom of stiffness specifically. There was significant diurnal variation in symp-
tom severity, but the worst time of day was not the same for everybody. The most straightfor-
ward way to assess the impact of stiffness was felt to be by assessing ability to do everyday
activities. In previous studies the Stanford Health Assessment Questionnaire, or the shorter
Modified Health Assessment Questionnaire, have been used; function correlates with other
measures of disease activity in PMR and is responsive to change [20, 21]. One participant sug-
gested directly measuring limb “functionality” as a way of assessing stiffness, again emphasising
the close relationship between stiffness and function.
Morning stiffness duration was felt to be a separate matter to stiffness severity, but duration
of morning stiffness was reported to vary from day to day; this raises the question of whether
the observed poor test-retest reliability of morning stiffness duration [6] may be due to fluctua-
tion of the symptom being measured, rather than unreliability of the measurement instrument
itself. Despite being under the care of rheumatologists, who use morning stiffness duration as
part of their construct of disease activity [18], patients still did not suggest stiffness duration as
a way of measuring stiffness. This suggests that it may not translate easily into a patient-re-
ported outcome measure. Our findings are indirectly supported by previous work in RA: a
cross-sectional study suggested that the description, severity and duration of “morning stiff-
ness” in rheumatoid arthritis was not very different from that reported by patients with “non-
inflammatory” joint disease, and that severity scores were associated with disease activity [22].
When stiffness was measured in patients with RA, “morning stiffness” severity and duration
were only moderately correlated, and severity was more responsive to change than duration
[23]. However, caution should be employed in extrapolating from one disease and patient pop-
ulation to another.
Limitations of this study include the restriction to the UK and those with English as a first
language. We did not require fulfilment of classification criteria for PMR, but all patients had
to be diagnosed by a rheumatologist. We did not take a quantitative approach, and as for any
qualitative study, generalizability outside this setting remains to be established. However, this
study sampled for a range of age, disease durations and disability; and recruited from three dif-
ferent hospitals in the UK, thereby accessing a range of disease experiences and care pathways.
At two of the centres the focus groups were co-facilitated by rheumatologists (SLM, CTP, RH).
The clinicians’ own experience and understanding of PMR would inevitably have influenced
the research process, but some clinical input was deemed important for an understanding of
the clinical trial context to which these findings would be ultimately applied. At these two cen-
tres focus groups were co-facilitated by a non-clinical researcher (MW), and critical self-reflec-
tion of facilitators’ prior knowledge, background and assumptions was encouraged. At the
third centre, the focus groups were facilitated entirely by rheumatology nurse researchers
trained in qualitative methods. Facilitators were all aware of the importance of focus group
methodology whereby the inquiry should come to surround the participants’ agenda and a
breadth of opinion is achieved [9]. Analysis was conducted independently by an experienced
qualitative researcher (MM), a non-clinical research assistant (MW) and one clinician (SLM).
During the project MM provided MW and SLM with informal training in reflexive analytical
skills. In addition, a key strength of this work is that patients were involved in data interpreta-
tion and preparation for publication [11]: two patients (JD, MN) analysed two transcripts and
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met with the analysts to ensure that the interpretation of the themes were accurate from their
perspective.
Basing the study around a genuine problem (How do we measure stiffness in PMR?) helped
to focus the research question, and we used theoretical concepts in outcomes research to devel-
op our conceptual model. This conceptual model, based on the eight themes identified during
the analysis, will inform the future development of a core outcome set in PMR.
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